气候变化领域集成服务门户(CCPortal): A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike

CCPortal

DOI	10.1073/pnas.2026153118
	A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike
	Lu M.; Dravid P.; Zhang Y.; Trivedi S.; Li A.; Harder O.; Mahesh K.C.; Chaiwatpongsakorn S.; Zani A.; Kenney A.; Zeng C.; Cai C.; Ye C.; Liang X.; Shimamura M.; Liu S.-L.; Mejias A.; Ramilo O.; Boyaka P.N.; Qiu J.; Martinez-Sobrido L.; Yount J.S.; Peeples M.E.; Kapoor A.; Niewiesk S.; Li J.
发表日期	2021
ISSN	00278424
卷号	118 期号:12
英文摘要	The current pandemic of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights an urgent need to develop a safe, efficacious, and durable vaccine. Using a measles virus (rMeV) vaccine strain as the backbone, we developed a series of recombinant attenuated vaccine candidates expressing various forms of the SARS-CoV-2 spike (S) protein and its receptor binding domain (RBD) and evaluated their efficacy in cotton rat, IFNAR−/−mice, IFNAR−/−-hCD46 mice, and golden Syrian hamsters. We found that rMeV expressing stabilized prefusion S protein (rMeV-preS) was more potent in inducing SARS-CoV-2–specific neutralizing antibodies than rMeV expressing full-length S protein (rMeV-S), while the rMeVs expressing different lengths of RBD (rMeV-RBD) were the least potent. Animals immunized with rMeV-preS produced higher levels of neutralizing antibody than found in convalescent sera from COVID-19 patients and a strong Th1-biased T cell response. The rMeV-preS also provided complete protection of hamsters from challenge with SARS-CoV-2, preventing replication in lungs and nasal turbinates, body weight loss, cytokine storm, and lung pathology. These data demonstrate that rMeV-preS is a safe and highly efficacious vaccine candidate, supporting its further development as a SARS-CoV-2 vaccine. © 2021 National Academy of Sciences. All rights reserved.
英文关键词	SARS-CoV-2 vaccine \| measles virus vector \| prefusion spike
语种	英语
scopus关键词	convalescent serum; coronavirus spike glycoprotein; measles vaccine; neutralizing antibody; vitronectin; coronavirus spike glycoprotein; neutralizing antibody; recombinant vaccine; virus antibody; animal cell; animal experiment; animal model; animal tissue; antibody production; Article; body weight loss; cellular immunity; comparative effectiveness; controlled study; coronavirus disease 2019; cotton rat; cytokine storm; drug efficacy; drug potency; drug safety; experimental lung injury; female; human; infection prevention; lung; mouse; nonhuman; priority journal; protein domain; protein expression; protein stability; rat; receptor binding; Severe acute respiratory syndrome coronavirus 2; Syrian hamster; Th1 cell; turbinate; virus expression; virus replication; virus spike; animal; complication; disease model; gene expression; gene vector; genetics; hamster; immunization; immunology; Measles virus; pathology; prevention and control; transgenic mouse; vaccine immunogenicity; Animals; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Cricetinae; Disease Models, Animal; Gene Expression; Genetic Vectors; Humans; Immunization; Immunogenicity, Vaccine; Measles virus; Mice; Mice, Transgenic; Rats; Spike Glycoprotein, Coronavirus; Vaccines, Synthetic
来源期刊	Proceedings of the National Academy of Sciences of the United States of America
文献类型	期刊论文
条目标识符	http://gcip.llas.ac.cn/handle/2XKMVOVA/180139
作者单位	Department of Veterinary Biosciences, Ohio State University, Columbus, OH 43210, United States; Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH 43205, United States; Department of Microbial Infection and Immunity, College of Medicine, Ohio State University, Columbus, OH 43210, United States; Department of Surgery, College of Medicine, Ohio State University, Columbus, OH 43210, United States; Texas Biomedical Research Institute, San Antonio, TX 78227, United States; Department of Pediatrics, College of Medicine, Ohio State University, Columbus, OH 43210, United States; Infectious Disease Institute, Ohio State University, Columbus, OH 43210, United States; Center for Retrovirus Research, Ohio State University, Columbus, OH 43210, United States; Department of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center, Kansas City, KS 66160, United States
推荐引用方式 GB/T 7714	Lu M.,Dravid P.,Zhang Y.,et al. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike[J],2021,118(12).
APA	Lu M..,Dravid P..,Zhang Y..,Trivedi S..,Li A..,...&Li J..(2021).A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike.Proceedings of the National Academy of Sciences of the United States of America,118(12).
MLA	Lu M.,et al."A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike".Proceedings of the National Academy of Sciences of the United States of America 118.12(2021).